304 related articles for article (PubMed ID: 37720537)
1. Controlled attenuation parameters to assess liver steatosis in obese patients with polycystic ovary syndrome.
Wang D; Nan N; Bing H; He B
Front Endocrinol (Lausanne); 2023; 14():1241734. PubMed ID: 37720537
[TBL] [Abstract][Full Text] [Related]
2. Non-alcoholic fatty liver disease is associated with insulin resistance and lipid accumulation product in women with polycystic ovary syndrome.
Macut D; Tziomalos K; Božić-Antić I; Bjekić-Macut J; Katsikis I; Papadakis E; Andrić Z; Panidis D
Hum Reprod; 2016 Jun; 31(6):1347-53. PubMed ID: 27076501
[TBL] [Abstract][Full Text] [Related]
3. [Effects of resolving method of Chinese medicine on the lipid metabolism in polycystic ovary syndrome accompanied with non-alcoholic fatty liver disease].
Chen Y; Wang XJ; Jin HL; Jin L
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2013 Jun; 33(6):751-6. PubMed ID: 23980352
[TBL] [Abstract][Full Text] [Related]
4. High-free androgen index is associated with increased risk of non-alcoholic fatty liver disease in women with polycystic ovary syndrome, independent of obesity and insulin resistance.
Cai J; Wu CH; Zhang Y; Wang YY; Xu WD; Lin TC; Li SX; Wang LH; Zheng J; Sun Y; Liu W; Tao T
Int J Obes (Lond); 2017 Sep; 41(9):1341-1347. PubMed ID: 28487551
[TBL] [Abstract][Full Text] [Related]
5. [Clinical features, hormonal profile, and metabolic abnormalities of obese women with obese polycystic ovary syndrome].
Li X; Lin JF
Zhonghua Yi Xue Za Zhi; 2005 Dec; 85(46):3266-71. PubMed ID: 16409817
[TBL] [Abstract][Full Text] [Related]
6. Metabolic disparities between obese and non-obese patients with polycystic ovary syndrome: implications for endometrial receptivity indicators.
Li XL; Ji YF; Feng Y; Liu SW
Gynecol Endocrinol; 2024 Dec; 40(1):2312895. PubMed ID: 38444321
[TBL] [Abstract][Full Text] [Related]
7. Prevalence and predictors of nonalcoholic fatty liver disease in South Asian women with polycystic ovary syndrome.
Shengir M; Krishnamurthy S; Ghali P; Deschenes M; Wong P; Chen T; Sebastiani G
World J Gastroenterol; 2020 Nov; 26(44):7046-7060. PubMed ID: 33311949
[TBL] [Abstract][Full Text] [Related]
8. Insulin resistance and hyperandrogenemia independently predict nonalcoholic fatty liver disease in women with polycystic ovary syndrome.
Harsha Varma S; Tirupati S; Pradeep TVS; Sarathi V; Kumar D
Diabetes Metab Syndr; 2019; 13(2):1065-1069. PubMed ID: 31336445
[TBL] [Abstract][Full Text] [Related]
9. Analyses of risk factors for polycystic ovary syndrome complicated with non-alcoholic fatty liver disease.
Zhang J; Hu J; Zhang C; Jiao Y; Kong X; Wang W
Exp Ther Med; 2018 May; 15(5):4259-4264. PubMed ID: 29725371
[TBL] [Abstract][Full Text] [Related]
10. Association of MEP1A gene variants with insulin metabolism in central European women with polycystic ovary syndrome.
Lam UD; Lerchbaum E; Schweighofer N; Trummer O; Eberhard K; Genser B; Pieber TR; Obermayer-Pietsch B
Gene; 2014 Mar; 537(2):245-52. PubMed ID: 24388959
[TBL] [Abstract][Full Text] [Related]
11. Hepatic manifestations of women with polycystic ovary syndrome.
Chen MJ; Ho HN
Best Pract Res Clin Obstet Gynaecol; 2016 Nov; 37():119-128. PubMed ID: 27107966
[TBL] [Abstract][Full Text] [Related]
12. Levels of lipoprotein and homocysteine in non-obese and obese patients with polycystic ovary syndrome.
Yilmaz M; Biri A; Bukan N; Karakoç A; Sancak B; Törüner F; Paşaoğlu H
Gynecol Endocrinol; 2005 May; 20(5):258-63. PubMed ID: 16019370
[TBL] [Abstract][Full Text] [Related]
13. Nonalcoholic fatty liver disease in women with polycystic ovary syndrome: associated factors and noninvasive fibrosis staging in a single Brazilian center.
Taranto DOL; Guimarães TCM; Couto CA; Cândido AL; Azevedo RCS; Mattos FS; Elias MLC; Reis FM; Rocha ALL; Faria LC
Arch Endocrinol Metab; 2020; 64(3):235-242. PubMed ID: 32555989
[TBL] [Abstract][Full Text] [Related]
14. Expression of Serum Omentin, CTRP9, and Vaspin in Patients with Polycystic Ovary Syndrome.
Wang Y; Liu N; Lu J; Yang L; Wang C; Chen J; Chang W
Evid Based Complement Alternat Med; 2022; 2022():1862404. PubMed ID: 36034953
[TBL] [Abstract][Full Text] [Related]
15. [Electroacupuncture combined with lifestyle control on obese nonalcoholic fatty liver disease: a randomized controlled trial].
Dong C; Zhang CR; Xue BY; Miu WF; Fang NY; Li K; Ou ZJ; Xu YQ
Zhongguo Zhen Jiu; 2020 Feb; 40(2):129-34. PubMed ID: 32100496
[TBL] [Abstract][Full Text] [Related]
16. Serum uric acid/creatinine ratio and free androgen index are synergistically associated with increased risk of polycystic ovary syndrome in obese women.
El-Eshmawy MM; Ibrahim A; Bahriz R; Shams-Eldin N; Mahsoub N
BMC Endocr Disord; 2022 Dec; 22(1):315. PubMed ID: 36514085
[TBL] [Abstract][Full Text] [Related]
17. Are serum chemerin levels different between obese and non-obese polycystic ovary syndrome women?
Yang S; Wang Q; Huang W; Song Y; Feng G; Zhou L; Tan J
Gynecol Endocrinol; 2016; 32(1):38-41. PubMed ID: 26291816
[TBL] [Abstract][Full Text] [Related]
18. Polycystic ovary syndrome with hyperandrogenism as a risk factor for non-obese non-alcoholic fatty liver disease.
Kim JJ; Kim D; Yim JY; Kang JH; Han KH; Kim SM; Hwang KR; Ku SY; Suh CS; Kim SH; Choi YM
Aliment Pharmacol Ther; 2017 Jun; 45(11):1403-1412. PubMed ID: 28370150
[TBL] [Abstract][Full Text] [Related]
19. Exploring the significance of sex hormone-binding globulin examination in the treament of women with polycystic ovarian syndrome (PCOS).
Lin XF; Wu RR; Du J; Liao YC; Du Y; Ye Y; Wang Y; Zhang XB; Wu C; Chen A
Clin Exp Obstet Gynecol; 2015; 42(3):315-20. PubMed ID: 26152001
[TBL] [Abstract][Full Text] [Related]
20. Sex Hormone-Binding Globulin (SHBG) Reduction: The Alarm Bell for the Risk of Non-Alcoholic Fatty Liver Disease in Adolescents with Polycystic Ovary Syndrome.
Urbano F; Chiarito M; Lattanzio C; Messa A; Ferrante M; Francavilla M; Mehmeti I; Lassandro G; Giordano P; Faienza MF
Children (Basel); 2022 Nov; 9(11):. PubMed ID: 36421197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
